Case Report

Anaesthesia Management and Use of Sugammadex in a Patient with Ullrich’s Disease

10.5152/TJAR.2015.22448

  • Emre Erbabacan
  • Güniz M. Köksal
  • Tuğçe Barça Şeker
  • Birsel Ekici
  • Rahsan Özcan
  • Fatiş Altindaş

Received Date: 04.09.2014 Accepted Date: 18.11.2014 Turk J Anaesthesiol Reanim 2015;43(5):356-359

Here, we report anaesthesia management and the successful use of total intravenous anaesthesia and sugammadex in a patient with Ullrich’s disease. Propofol and remifentanyl infusion was used for anaesthesia. After the end of the surgery, when the train-of-four value was 0%, 4 mg kg−1 sugammadex was administered, and the patient was successfully extubated after 36 s. No adverse effects or safety concerns were observed. In conclusion, we suggest that the use of propofol infusion to avoid the use of inhalation anaesthetics and the use of sugammadex for the reversal of the effects of rocuronium is safe in patients with Ullrich’s disease.

Keywords: Sugammadex, muscular dystrophy, total intravenous anaesthesia